<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049399</url>
  </required_header>
  <id_info>
    <org_study_id>NP031112-08B02</org_study_id>
    <nct_id>NCT01049399</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy</brief_title>
  <acronym>Tauros</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noscira SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>i3 Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Noscira SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine wether NP031112 is safe and effective in the&#xD;
      treatment of mild to moderate Progressive Supranuclear Palsy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from Baseline between the 2 active study medication groups compared with the placebo group in the Progressive Supranuclear Palsy Rating Scale of Golbe</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AEs and patients with an incidence rate of â‰¥ 5% AEs</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Modified Schwab and England Scale</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Timed Up and Go Test (quantitative motor function)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in cognitive function(Dementia Rating Scale-2,Frontal Assessment Battery,category and letter verbal fluency)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Starkstein Apathy Scale (behavior)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in functional assessments(Unified Parkinson Disease rating Scale part II and European Quality of Life questionnaire)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Change</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline between 2 active study medication groups vs placebo group in Clinical Global Impression of Severity</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once daily administration of powder for oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP031112 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group dosed with 800 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP031112 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group treated with 600 mg once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tideglusib</intervention_name>
    <description>800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>NP031112 800 mg</arm_group_label>
    <other_name>NP031112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tideglusib</intervention_name>
    <description>600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>NP031112 600 mg</arm_group_label>
    <other_name>NP031112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>powder for oral suspension administered once daily in fasting conditions for 52 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women with diagnosis of possible or probable PSP according to clinical&#xD;
             criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP&#xD;
             (Appendix 1).&#xD;
&#xD;
          2. Age of 40 to 85 years (patients over 85 years could be included after previous&#xD;
             assessment by Investigator and approved by sponsor).&#xD;
&#xD;
          3. Brain magnetic resonance imaging (MRI) study within 24 months before Baseline visit&#xD;
             excluding other potential causes of parkinsonism, especially cerebrovascular lesions&#xD;
             and space occupying lesions.&#xD;
&#xD;
          4. Mild-to-moderate stage of disease severity according to score of 1 to 4 in Golbe&#xD;
             Staging System.(Appendix 2)&#xD;
&#xD;
          5. Female patients must be surgically sterilized; at least 1 year postmenopausal&#xD;
             (confirmed by follicle-stimulating hormone [FSH] &gt;20 international units [IUs]); using&#xD;
             adequate birth control (implants, injectables, combined oral contraceptives,&#xD;
             intrauterine contraceptive device, total sexual abstinence during the study or&#xD;
             vasectomised partner). Male patients must be willing to use barrier contraception&#xD;
             (condom) during the study and for 6 months after last treatment administration.&#xD;
&#xD;
             In European arms of study female patients must be without childbearing potential.&#xD;
&#xD;
          6. Caregiver (or dedicated nurse) living in same household or interacting with patient&#xD;
             for &gt;4 hours every day able to assure correct preparation and administration of study&#xD;
             drug.&#xD;
&#xD;
          7. Patients living at home or in retirement home not requiring continuous nursing care.&#xD;
&#xD;
          8. General health status acceptable for participation in 64-week clinical trial.&#xD;
&#xD;
          9. Ability to swallow 100 mL of water suspension.&#xD;
&#xD;
         10. Any concomitant medication for PSP must be well-tolerated and unchanged for at least 1&#xD;
             month prior to Baseline visit and its dose and regimen should be maintained during&#xD;
             study if there are no clinical reasons to modify it.&#xD;
&#xD;
         11. Occupational, physical, respiratory, or speech therapy is allowed but it must be&#xD;
             stable for at least 1 month prior to screening.&#xD;
&#xD;
         12. Pharmacological treatment of any other chronic condition must be stable and&#xD;
             well-tolerated for at least 1 month prior to screening. Analgesics, occasional per&#xD;
             request nonsteroidal anti-inflammatory agents, and treatments for transient or&#xD;
             emergent conditions are allowed.&#xD;
&#xD;
         13. Signed informed consent by patient and permitted prior to initiation of any&#xD;
             study-specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Failure to perform screening or baseline examinations.&#xD;
&#xD;
          2. Hospitalization or change of chronic concomitant medication 1 month prior to or during&#xD;
             screening period (apart from pre-planned hospitalization for a condition, which did&#xD;
             not deteriorate since 1 month prior to screening period).&#xD;
&#xD;
          3. Clinical, laboratory or neuroimaging findings consistent with:&#xD;
&#xD;
               -  other primary degenerative diseases such as Parkinson's disease; dementia with&#xD;
                  Lewy bodies; corticobasal degeneration; frontotemporal dementia; multiple system&#xD;
                  atrophy; parkinsonism-dementia complex of Guam, Kii or Guadeloupe; Alzheimer's&#xD;
                  disease; amyotrophic lateral sclerosis; Creutzfeldt-Jakob Disease; Huntington's&#xD;
                  disease; Down's syndrome; etc.&#xD;
&#xD;
               -  cerebrovascular disease as major, strategic or multilacunar infarcts, or&#xD;
                  extensive white matter lesions scoring 3 in the Wahlund's scale [Wahlund et al.,&#xD;
                  2001].&#xD;
&#xD;
               -  other central nervous system diseases (hydrocephalus, severe head trauma,&#xD;
                  tumours, subdural haematoma or other relevant space occupying processes, etc.).&#xD;
&#xD;
               -  epilepsy.&#xD;
&#xD;
               -  other infectious, metabolic or systemic diseases affecting central nervous system&#xD;
                  (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency,&#xD;
                  clinically significant serum electrolyte disturbances, juvenile onset diabetes&#xD;
                  mellitus, etc.).&#xD;
&#xD;
          4. A current Diagnostic and Statistical Manual of Mental Disorders Fourth Edition&#xD;
             (DSM-IV) diagnosis of active major depression, schizophrenia or bipolar disorder.&#xD;
&#xD;
          5. Clinically significant, advanced or unstable disease that may interfere with primary&#xD;
             or secondary variable evaluations, may bias clinical or mental assessment or put&#xD;
             patient at special risk, such as:&#xD;
&#xD;
               -  chronic liver disease, as indicated by liver function test abnormalities (ALAT,&#xD;
                  ASAT, bilirubin or GGT out of range) positive serology for Hepatitis C, or other&#xD;
                  manifestations of liver disease&#xD;
&#xD;
               -  respiratory insufficiency&#xD;
&#xD;
               -  renal insufficiency (serum creatinine &gt;2 mg/dL (&gt;150 micromol/L) and creatinine&#xD;
                  clearance &lt;60 (according to Cockcroft-Gault formula)&#xD;
&#xD;
               -  heart disease (myocardial infarction, unstable angina, heart failure,&#xD;
                  cardiomyopathy within 6 months before screening).&#xD;
&#xD;
               -  bradycardia (heart beat &lt;50/min) or tachycardia (heart beat &gt;95/min)&#xD;
&#xD;
               -  episodes of unstable or uncontrolled hypertension (systolic pressure &gt;160 mm Hg&#xD;
                  or diastolic pressure &gt;100 mm Hg) or hypotension (systolic pressure &lt;90 mm Hg or&#xD;
                  diastolic pressure &lt;45 mm Hg) during 2 months prior to Baseline visit.&#xD;
&#xD;
               -  atrioventricular block (type II / Mobitz II and type III), congenital long QT&#xD;
                  syndrome, sinus node dysfunction or prolonged QTcF interval (males &gt;450 msec and&#xD;
                  females &gt;470 msec using Fridericia's formula: QTc = QT/cube root of RR).&#xD;
&#xD;
               -  uncontrolled diabetes mellitus.&#xD;
&#xD;
               -  malignant tumors within last 5 years except skin malignancies (other than&#xD;
                  melanoma) or indolent prostate cancer.&#xD;
&#xD;
               -  metastases.&#xD;
&#xD;
          6. Disability that may prevent the patient from completing all study requirements (e.g.,&#xD;
             blindness, deafness, and severe language difficulty).&#xD;
&#xD;
          7. Chronic daily drug intake of:&#xD;
&#xD;
               -  drugs metabolized by cytochrome P450 (CYP)3A4 with narrow therapeutic window&#xD;
                  (acenocoumarol, warfarin, and digitoxin)&#xD;
&#xD;
               -  anticonvulsants indicated for epileptic seizures&#xD;
&#xD;
               -  systemic anticholinergics with relevant action on central nervous system&#xD;
&#xD;
               -  acetylcholinesterase inhibitors&#xD;
&#xD;
               -  neuroleptics except quetiapine, clozapine or other atypical neuroleptics&#xD;
&#xD;
               -  nootropics such as piracetam, propentofylline, hydergine, vinpocetine, ginkgo&#xD;
                  biloba, coenzyme Q-10, idebenone and derivatives&#xD;
&#xD;
               -  centrally active anti-hypertensive drugs such as clonidine, alpha methyl dopa,&#xD;
                  guanidine, and guanfacine&#xD;
&#xD;
               -  systemic cortico-steroids or immunosuppressants&#xD;
&#xD;
               -  systemic nonsteroidal anti-inflammatory agents (except taken as occasional&#xD;
                  medication per request or acetylsalicylic acid up to 100 mg/day as an&#xD;
                  antiplatelet agent).&#xD;
&#xD;
               -  memantine, lithium, valproic acid or other GSK-3 inhibitors within 3 months prior&#xD;
                  to the Baseline visit.&#xD;
&#xD;
          8. Suspected or known history of drug abuse or excessive alcohol intake*&#xD;
&#xD;
          9. Suspected or known allergy to any components of study treatments.&#xD;
&#xD;
         10. Enrollment in another investigational drug study within 3 months before Baseline&#xD;
             visit.&#xD;
&#xD;
         11. Any condition, which in the opinion of Investigator makes patient unsuitable for&#xD;
             inclusion or likely to be non-compliant.&#xD;
&#xD;
               -  More than 21 units per week for men and 14 for women; or consumption of more than&#xD;
                  8 units in a single episode. 1 unit equals approximately 1 glass of wine, 250 ml&#xD;
                  of beer or 1 shot (25 ml) of spirit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Parkinson's and Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Movement Disorders, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry, Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Fachkrankenhaus fÃ¼r BewegungsstÃ¶rungen/Parkinson Beelitz</name>
      <address>
        <city>Beelitz-HeilstÃ¤tten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldt Universitat Charite, Campus Virchow, Neurologisch</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl-Guslav-Carus, Technische Universitat Dresden, Klinik und Poliklinik fur Neurologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Neurologie 0E 7210</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Nervenheilkunde. Klinik fur Neurologie mit Poliklinik.</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen,Eberhard-Karls-Universitat, Universitatsklinikum Neurologie</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³ Ace</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpto.neurologia. H. Clinic.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. Neurologia. Hospital RamÃ³n y Cajal.</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua Terrassa</name>
      <address>
        <city>Terrasa</city>
        <zip>8221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement of Neurology, Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>460009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre for Neurology and Neurosurgery NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reta Lila Weston Institute of Neurological Studies,Sara Koe PSP Research Centre</name>
      <address>
        <city>London</city>
        <zip>WC1N 1PJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Ageing Research Unit</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 24, 2012</submitted>
    <returned>November 23, 2012</returned>
    <submitted>November 23, 2012</submitted>
    <returned>December 21, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

